Skip to main content
SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. logo

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. — Investor Relations & Filings

Ticker · 688238 ISIN · CNE1000059N9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 486 across all filing types
Latest filing 2024-04-24 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688238

About SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD.

https://www.obio-tech.com/

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. is a specialized Contract Development and Manufacturing Organization (CDMO) focused on the gene and cell therapy (GCT) sector. The company provides end-to-end solutions encompassing vector construction, process development, analytical method development, and large-scale GMP manufacturing. Its service portfolio includes the production of viral vectors such as adeno-associated virus (AAV), lentivirus, adenovirus, and oncolytic viruses, as well as plasmid DNA and cell therapy products. Obio Technology supports clients from early-stage research through clinical trials to commercialization. The company operates advanced facilities designed to meet international regulatory standards, facilitating the development of innovative genetic medicines and advanced therapies for global biopharmaceutical partners.

Recent filings

Filing Released Lang Actions
《2023年度独立董事述职报告》（宋正奇）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2023 by an independent director of the company. It details the director's background, attendance at board and committee meetings, oversight activities, and governance matters during the year. It includes no financial statements or detailed financial data but focuses on governance, director duties, and compliance with regulations. This type of document is a report by a board member on their activities and governance role, which fits best under Board/Management Information (MANG). The document length is about 4839 characters, which is sufficient for a detailed report but does not contain financial results or audit data. Therefore, the classification is MANG with high confidence.
2024-04-24 Chinese
天健会计师事务所（特殊普通合伙）关于和元生物技术（上海）股份有限公司关于营业收入扣除情况的专项核查意见
Regulatory Filings
2024-04-24 Chinese
《2023年度独立董事述职报告》（甘丽凝）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2023 by 甘丽凝, an independent director of 和元生物技术（上海）股份有限公司. It details the independent director's duties, attendance at board and committee meetings, oversight activities, and governance matters during the year. It references compliance with laws and company bylaws, internal control evaluations, and corporate governance activities. The document is a detailed report on the independent director's annual duties and governance oversight rather than a general annual report, audit report, or other financial filings. It is not a short announcement or certification but a substantive report on board/management information, specifically about the independent director's role and activities. Therefore, the most appropriate classification is Board/Management Information (MANG).
2024-04-24 Chinese
关于预计2024年度日常关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's expected 2024 annual related party transactions. It includes details about the nature of these transactions, the approval process by the board, independent directors, and supervisory board, and confirms that these transactions will be submitted for shareholder approval. The document does not contain financial statements or detailed financial performance data but rather focuses on governance and compliance related to related party transactions. It is a regulatory announcement about corporate governance and related party dealings, not a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS).
2024-04-24 Chinese
第三届董事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 13th meeting of the third board of directors of Heyuan Biotech (Shanghai) Co., Ltd. It includes approvals of various reports such as the 2023 Annual Report and its summary, the 2023 General Manager's Work Report, the 2023 Board Work Report, independent directors' reports, internal control evaluation, financial statements audited by an accounting firm, and other governance and financial matters. The document repeatedly states that the actual reports are published on the Shanghai Stock Exchange website and that these resolutions will be submitted to the shareholders' meeting for approval. The document itself does not contain the full annual report or financial statements but is a formal board meeting resolution announcement regarding these reports and related governance matters. Given the nature of the content—board meeting resolutions about annual reports and related documents—and the fact that it is an announcement of these approvals rather than the reports themselves, the filing type best fits Board/Management Information (MANG). The document is not a full Annual Report (10-K) or Audit Report (AR) because it does not contain the full financial statements or audit opinions but references them. It is also not a Regulatory Filing (RNS) because it is a formal board meeting resolution announcement. Therefore, the classification is MANG with high confidence.
2024-04-24 Chinese
会计师事务所2023年度履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm (auditor) for the year 2023. It discusses the auditor's qualifications, independence, audit scope, communication with the audit committee, and the issuance of an unqualified audit opinion on the company's 2023 financial statements. The document references the audit of the 2023 annual financial report and internal controls but does not contain the financial statements or detailed financial data itself. It is an assessment and summary of the auditor's work and performance rather than the audit report or the annual report itself. The document length is relatively short (2268 characters), and it serves as a standalone audit performance evaluation. This fits the category of an Audit Report / Information (AR), which includes standalone audit reports and evaluations of audit work, excluding full annual reports. Therefore, the correct classification is AR with high confidence. FY 2023
2024-04-24 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.